Legend Biotech Corp
NASDAQ:LEGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Legend Biotech Corp
NASDAQ:LEGN
|
US |
|
Futaba Industrial Co Ltd
TSE:7241
|
JP |
|
Mitsui Mining and Smelting Co Ltd
TSE:5706
|
JP |
Legend Biotech Corp
Legend Biotech Corp., an emerging leader in the biotechnology arena, has carved out a niche at the forefront of cellular therapeutics, focusing on transforming cancer treatment paradigms. Born out of the ambition to explore innovative medical frontiers, Legend Biotech embarked on a mission to develop Car-T cell therapies—a personalized form of immunotherapy that employs genetically altered T-cells to target and eradicate cancer cells. With its signature product, Carvykti (ciltacabtagene autoleucel), Legend Biotech has been making waves in the oncology sector. By redirecting the body's own immune system against multiple myeloma, a rare and challenging form of cancer, the company has demonstrated the potential to achieve deep and lasting remissions, bringing hope where conventional treatments may fall short.
The financial model of Legend Biotech is driven by strategic partnerships, extensive research and development initiatives, and successful navigation through complex regulatory landscapes. Partnering with Johnson & Johnson's subsidiary Janssen Biotech, the collaboration capitalizes on their combined expertise to advance Car-T technology. Revenues primarily flow from milestone payments upon achieving specific developmental goals, along with royalties derived from global sales of their breakthrough treatments. By investing heavily in R&D and ensuring a robust pipeline of therapeutic candidates, Legend Biotech positions itself for sustainable growth, striving to extend their innovative treatments to a broader range of cancers and, eventually, achieve profitability through expanded indications and market reach.
Legend Biotech Corp., an emerging leader in the biotechnology arena, has carved out a niche at the forefront of cellular therapeutics, focusing on transforming cancer treatment paradigms. Born out of the ambition to explore innovative medical frontiers, Legend Biotech embarked on a mission to develop Car-T cell therapies—a personalized form of immunotherapy that employs genetically altered T-cells to target and eradicate cancer cells. With its signature product, Carvykti (ciltacabtagene autoleucel), Legend Biotech has been making waves in the oncology sector. By redirecting the body's own immune system against multiple myeloma, a rare and challenging form of cancer, the company has demonstrated the potential to achieve deep and lasting remissions, bringing hope where conventional treatments may fall short.
The financial model of Legend Biotech is driven by strategic partnerships, extensive research and development initiatives, and successful navigation through complex regulatory landscapes. Partnering with Johnson & Johnson's subsidiary Janssen Biotech, the collaboration capitalizes on their combined expertise to advance Car-T technology. Revenues primarily flow from milestone payments upon achieving specific developmental goals, along with royalties derived from global sales of their breakthrough treatments. By investing heavily in R&D and ensuring a robust pipeline of therapeutic candidates, Legend Biotech positions itself for sustainable growth, striving to extend their innovative treatments to a broader range of cancers and, eventually, achieve profitability through expanded indications and market reach.
Sales Momentum: CARVYKTI net trade sales were approximately $555 million in Q4 2025, up 66% year‑over‑year, driven by U.S. ($420M) and strong ex‑U.S. growth ($135M).
Scale & Access: More than 10,000 patients treated, 294 global treatment sites across 14 markets and installed manufacturing capacity to support 10,000 annual doses (plans to expand toward 20,000).
Earlier‑line Shift: Management said ~65% of CARVYKTI patients are now in second‑to‑fourth line; data presented at ASH/Tandem show better outcomes with earlier use.
Manufacturing & Quality: High manufacturing success reported (company cited a 97% success rate earlier and 99% successful commercial manufacturing in a July 2024–Oct 2025 analysis); out‑of‑spec rates were 6.5% for 1–3 prior lines vs 9.2% for 4+ prior lines.
Profitability Path: CARVYKTI became profitable in 2025; company expects company‑wide profitability in 2026 and said it is confident in delivering ~50% topline growth for CARVYKTI in 2026 (management aligned with Street consensus).
Financials & Cash: Total revenue $306 million in Q4, up 64% YoY; gross margin 61%; cash and equivalents $949 million. Adjusted net income turned positive to $2.5 million (adjusted diluted EPS $0.01).
R&D & Pipeline: Active next‑gen programs (allogeneic gamma‑delta, in‑vivo candidates) with plans to file 1–2 U.S. INDs this year and present first in‑vivo clinical data potentially mid‑year.
Commercial Priorities: Continued focus on earlier‑line uptake, community adoption (1/3 of U.S. activated centers are community hospitals), bridging strategies to reduce neurotoxicity, and selective business development for complementary technologies.
